Clinical Trial Update: Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated the efficacy and safety of Ingavirin 90 mg once daily for influenza and other acute viral infections in adults and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Cold
• Respiratory Infection

Drugs mentioned

• Ingavirin

Snippet

Sponsor: Valenta Pharm JSC | Conditions: Common Cold, Influenza, Human | Phase 4 | Status: COMPLETED